Tislelizumab for treating locally advanced or metastatic non-squamous non-small-cell lung cancer without EGFR or ALK genomic tumour aberrations

Published on 01 Aug 2025
Last Updated on 01 Aug 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Tislelizumab 100 mg/10 mL concentrate for solution for infusion, in combination with platinum-doublet chemotherapy, for untreated locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), in patients whose tumours have programmed death-ligand 1 (PD-L1) expression on ≥50% of tumour cells, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase genomic tumour aberrations. Patients with locally advanced non-squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.

Funding status

Tislelizumab 100 mg/10 mL concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2025.

Clinical indication, subsidy class and MediShield Life claim limit for tislelizumab are provided in the Annex.

Tislelizumab for treating locally advanced or metastatic non-squamous NSCLC without EGFR or ALK genomic tumour aberrations [PDF, 155 KB]

PES Tislelizumab for treating non-small-cell lung cancer without EGFR or ALK mutations [PDF, 68 KB]